290 related articles for article (PubMed ID: 19157860)
1. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.
Mouawad R; Spano JP; Comperat E; Capron F; Khayat D
Eur J Cancer; 2009 May; 45(8):1407-14. PubMed ID: 19157860
[TBL] [Abstract][Full Text] [Related]
2. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma.
Wobser M; Siedel C; Schrama D; Bröcker EB; Becker JC; Vetter-Kauczok CS
Arch Dermatol Res; 2006 Feb; 297(8):352-7. PubMed ID: 16395613
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node.
Saintigny P; Kambouchner M; Ly M; Gomes N; Sainte-Catherine O; Vassy R; Czernichow S; Letoumelin P; Breau JL; Bernaudin JF; Kraemer M
Lung Cancer; 2007 Nov; 58(2):205-13. PubMed ID: 17686546
[TBL] [Abstract][Full Text] [Related]
4. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
5. High VEGFR-3-positive circulating lymphatic/vascular endothelial progenitor cell level is associated with poor prognosis in human small cell lung cancer.
Bogos K; Renyi-Vamos F; Dobos J; Kenessey I; Tovari J; Timar J; Strausz J; Ostoros G; Klepetko W; Ankersmit HJ; Lang G; Hoda MA; Nierlich P; Dome B
Clin Cancer Res; 2009 Mar; 15(5):1741-6. PubMed ID: 19240177
[TBL] [Abstract][Full Text] [Related]
6. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
7. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
Mouawad R; Soubrane C; Rixe O; Khayat D; Spano JP
Melanoma Res; 2006 Aug; 16(4):335-40. PubMed ID: 16845329
[TBL] [Abstract][Full Text] [Related]
8. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
[TBL] [Abstract][Full Text] [Related]
9. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
10. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma.
Yokoyama Y; Charnock-Jones DS; Licence D; Yanaihara A; Hastings JM; Holland CM; Emoto M; Sakamoto A; Sakamoto T; Maruyama H; Sato S; Mizunuma H; Smith SK
Clin Cancer Res; 2003 Apr; 9(4):1361-9. PubMed ID: 12684405
[TBL] [Abstract][Full Text] [Related]
11. Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression.
Kurschat P; Eming S; Nashan D; Krieg T; Mauch C
Br J Dermatol; 2007 Apr; 156(4):653-8. PubMed ID: 17263813
[TBL] [Abstract][Full Text] [Related]
12. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
13. Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma.
Maekawa S; Iwasaki A; Shirakusa T; Enatsu S; Kawakami T; Kuroki M; Kuroki M
Anticancer Res; 2007; 27(6A):3735-41. PubMed ID: 17970036
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
Mylona E; Alexandrou P; Mpakali A; Giannopoulou I; Liapis G; Markaki S; Keramopoulos A; Nakopoulou L
Eur J Surg Oncol; 2007 Apr; 33(3):294-300. PubMed ID: 17129704
[TBL] [Abstract][Full Text] [Related]
15. The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases.
Bando H; Weich HA; Horiguchi S; Funata N; Ogawa T; Toi M
Oncol Rep; 2006 Mar; 15(3):653-9. PubMed ID: 16465426
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
[TBL] [Abstract][Full Text] [Related]
17. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
18. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.
Ocvirk J; Stabuc B; Rudolf Z; Galvani V; Curin-Serbec V
Melanoma Res; 2000 Jun; 10(3):253-8. PubMed ID: 10890379
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.
Park HR; Min K; Kim HS; Jung WW; Park YK
Pathol Res Pract; 2008; 204(8):575-82. PubMed ID: 18440723
[TBL] [Abstract][Full Text] [Related]
20. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma.
Vihinen PP; Hilli J; Vuoristo MS; Syrjänen KJ; Kähäri VM; Pyrhönen SO
Acta Oncol; 2007; 46(5):678-84. PubMed ID: 17562445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]